Cargando…

Prevention of anastrozole induced bone loss with monthly oral ibandronate: Final 5 year results from the ARIBON trial

PURPOSE: The ARIBON trial is a double blind, randomised, placebo controlled study designed to evaluate the impact of ibandronate on bone mineral density (BMD) in women taking anastrozole for adjuvant treatment of breast cancer. METHODS: 131 postmenopausal women with early breast cancer were recruite...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lester, J.E., Dodwell, D., Brown, J.E., Purohit, O.P., Gutcher, S.A., Ellis, S.P., Thorpe, R., Horsman, J.M., Coleman, R.E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4723320/ https://www.ncbi.nlm.nih.gov/pubmed/26909256 http://dx.doi.org/10.1016/j.jbo.2012.06.002

Ejemplares similares

Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom
por: Lester, J E, et al.
Publicado: (2006)

Bone resorption predicts for skeletal complications in metastatic bone disease
por: Brown, J E, et al.
Publicado: (2003)

Anastrozole Improves Final Adult Height in Severe Hypothyroidism With Rapid Pubertal Progression
por: Hodax, Juanita K, et al.
Publicado: (2021)

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia.
por: Ralston, S. H., et al.
Publicado: (1997)

Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
por: Cairns, Junmei, et al.
Publicado: (2020)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis
por: Nakamura, T., et al.
Publicado: (2015)

Response of Mouse Breast Cancer Cells to Anastrozole, Tamoxifen, and the Combination
por: Xanthopoulos, J. M., et al.
Publicado: (2005)

Effects of ibandronate-hydroxyapatite on resorptive activity of osteoclasts
por: Zhang, Xiaohui, et al.
Publicado: (2011)

Treatment of Polyostotic Fibrous Dysplasia With Intravenous Ibandronate
por: Kazi, Fatima M, et al.
Publicado: (2021)

Effects of psoralen on the pharmacokinetics of anastrozole in rats
por: Zhang, Yuzhu, et al.
Publicado: (2018)

Ibandronate Treatment Before and After Implant Insertion Impairs Osseointegration in Aged Rats with Ovariectomy Induced Osteoporosis
por: Lotz, Ethan M., et al.
Publicado: (2019)

Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
por: Devitt, Bianca, et al.
Publicado: (2008)

Quarterly intravenous injection of ibandronate to treat osteoporosis in postmenopausal women
por: Sambrook, Philip
Publicado: (2007)

Gastrointestinal tolerability with ibandronate after previous weekly bisphosphonate treatment
por: Derman, Richard, et al.
Publicado: (2009)

Ibandronate: The loading dose concept in the treatment of metastatic bone pain
por: Maier, Gerrit Steffen, et al.
Publicado: (2015)

Comparative Effects of Ibandronate and Paclitaxel on Immunocompetent Bone Metastasis Model
por: Chung, Yoon-Sok, et al.
Publicado: (2015)

Anastrozole (Arimidex ™) – an aromatase inhibitor for the adjuvant setting?
por: Buzdar, A U
Publicado: (2001)

A randomized trial to assess the biological activity of short-term (pre-surgical) fulvestrant 500 mg plus anastrozole versus fulvestrant 500 mg alone or anastrozole alone on primary breast cancer
por: Robertson, John FR, et al.
Publicado: (2013)

Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study*
por: COOPER, A, et al.
Publicado: (2006)

Anastrozole-Induced Dermatitis: Report of a Woman with an Anastrozole-Associated Dermatosis and a Review of Aromatase Inhibitor-Related Cutaneous Adverse Events
por: Kim, Yoo Jung, et al.
Publicado: (2020)

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis
por: Bauss, Frieder, et al.
Publicado: (2006)

Predictors of Ibandronate Efficacy for the Management of Osteoporosis: A Meta-Regression Analysis
por: Ma, Zeren, et al.
Publicado: (2016)

Local Application of Ibandronate/Gelatin Sponge Improves Osteotomy Healing in Rabbits
por: Yang, Zongyou, et al.
Publicado: (2015)

Preparation and Properties of New Co-Crystals of Ibandronate with Gluco- or Galactopyranoside Derivatives †
por: Oktabec, Zbynek, et al.
Publicado: (2010)

A prospective comparative study of intravenous alendronate and ibandronate for the treatment of osteoporosis
por: Horikawa, Akira, et al.
Publicado: (2019)

Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia
por: Sestak, Ivana, et al.
Publicado: (2019)

Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation
por: Regenthal, Ralf, et al.
Publicado: (2018)

Hormonal based treatment of ovarian anaplastic ependymoma with anastrozole
por: Gorski, Justin Wayne, et al.
Publicado: (2017)

Anastrozole plus leuprorelin in early maturing girls with compromised growth: the “GAIL” study
por: Papadimitriou, D. T., et al.
Publicado: (2015)

Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance?
por: Geisler, J
Publicado: (2011)

Effect of ibandronate on bending strength and toughness of rodent cortical bone: Possible implications for fracture prevention
por: Savaridas, T., et al.
Publicado: (2015)

Long-term efficacy, safety, and patient acceptability of ibandronate in the treatment of postmenopausal osteoporosis
por: Inderjeeth, Charles A, et al.
Publicado: (2014)

Osteoprotegerin genetic polymorphisms and their influence on therapeutic response to ibandronate in postmenopausal osteoporotic females
por: Tariq, Saba, et al.
Publicado: (2023)

Anastrozole: Deep vein thrombosis and pulmonary embolism: case report
Publicado: (2021)

Escitalopram co-prescription in anastrozole-treated breast cancer patients
por: Ozyurt, Hazan, et al.
Publicado: (2022)

Improvement of Bone Physiology and Life Quality Due to Association of Risedronate and Anastrozole
por: Monda, Vincenzo, et al.
Publicado: (2017)

Efficacy of anastrozole after tamoxifen in early breast cancer patients with chemotherapy‐induced ovarian function failure
por: van Hellemond, Irene E.G., et al.
Publicado: (2019)

The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer
por: Dowsett, M, et al.
Publicado: (1999)

Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells
por: Thaler, R., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_7krcu973075t65lnaoq72gcapr